NHLBI Awarded Starlight Cardiovascular A $2.16M NIH SBIR Phase II Grant

NHLBI

by

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has awarded Starlight Cardiovascular, Inc. a Small Business Innovation Research (SBIR) Phase II grant to advance the development of its Ductus Arteriosus Stent System.

The grant will provide $2,158,183 to support preclinical testing of a stent designed to allow blood flow between the pulmonary and systemic circulations in patients with critical Congenital Heart Disease (CHD).

CHD is the most common type of birth defect, affecting 1.3 million babies worldwide each year. Babies born with critical CHD require intervention to survive, and the current standard of care is open-chest surgery.

The Ductus Arteriosus Stent System is being developed by Starlight Cardiovascular as a minimally invasive alternative to surgery.

The National Heart, Lung, and Blood Institute of the National Institutes of Health is funding this research through grant R44HL158304. The author is solely responsible for the content of this press release, which does not necessarily represent the official views of the NIH.

Starlight Cardiovascular is a medical technology company in the preclinical stage that is developing a portfolio of devices to treat pediatric Congenital Heart Disease.

Related Stories

Latest News Stories

Discover more from Silicon Valley Journals

Subscribe now to keep reading and get access to the full archive.

Continue reading